Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Short Contact Ameluz PDT for Actinic Keratosis
NCT06027619Phase 2Completed
- Sponsor
- Case Comprehensive Cancer Center
- Start
- Oct 2023
- Primary completion
- Jul 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of aminolevulinic acid 10% gel in actinic keratosis (AK) (3 arms), sponsored by Case Comprehensive Cancer Center. Primary endpoints: Treatment Efficacy Based on Participant AK Lesion Clearance at 6 months and Differences in Pain Level Reported Throughout Exposure to Red Light at 2 months. Started Oct 2023; status: completed.
02
Drugs
aminolevulinic acid 10% gel
03
Conditions
actinic keratosis (AK)
Beyond the preview
Go deeper on NCT06027619.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06027619.